Qualigen Therapeutics receives Nasdaq non-compliance notice for audit committee composition

AIxCrypto Holdings, Inc.

Notice received Oct 18, 2024, after director Matt Korenberg resigned from Board and Audit Committee effective Oct 3, 2024.
Audit Committee now has only two independent directors (Robert Lim, Cody Price); needs three per Nasdaq Rule 5605.
Cure period: earlier of next annual meeting or Oct 5, 2025; if meeting before Apr 1, 2025, compliance due by Apr 1, 2025.
Company plans to appoint one independent director to Audit Committee during the cure period.
No immediate effect on listing or trading of QLGN common stock on The Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.